TGF-β1 Increases Resistance of NIH/3T3 Fibroblasts Toward Apoptosis Through Activation of Smad2/3 and Erk1/2 Pathways

Ulugbek Negmadjanov; Alisher Holmuhamedov; Larisa Emelyanova; Hao Xu; Farhan Rizvi; Gracious R Ross; A. Jamil Tajik; Yang Shi; Ekhson Holmuhamedov; Arshad Jahangir

Journal ArticleOPEN ACCESS

TGF-β1 Increases Resistance of NIH/3T3 Fibroblasts Toward Apoptosis Through Activation of Smad2/3 and Erk1/2 Pathways

Negmadjanov U
Holmuhamedov A
Emelyanova L
et al.

Journal of Patient-Centered Research and Reviews (2016) 3(4) 187-198

DOI: 10.17294/2330-0698.1407

N/ACitations

11Readers

Abstract

The mission of the Journal of Patient-Centered Research and Reviews (JPCRR) is to further the ongoing quest for new knowledge by providing a medium for the communication of clinical research, with the purpose of improving the quality of human health, the care of the individual patient, and the care of populations. A. TGF-β1 increases resistance of NIH/3T3 fibroblasts toward apoptosis through activation of Smad2/3 and Erk1/2 pathways.

Cite

CITATION STYLE

APA

Negmadjanov, U., Holmuhamedov, A., Emelyanova, L., Xu, H., Rizvi, F., Ross, G. R., … Jahangir, A. (2016). TGF-β1 Increases Resistance of NIH/3T3 Fibroblasts Toward Apoptosis Through Activation of Smad2/3 and Erk1/2 Pathways. Journal of Patient-Centered Research and Reviews, 3(4), 187–198. https://doi.org/10.17294/2330-0698.1407

TGF-β1 Increases Resistance of NIH/3T3 Fibroblasts Toward Apoptosis Through Activation of Smad2/3 and Erk1/2 Pathways

Abstract

Cite

Register to see more suggestions